Micro-cognition biomarkers redefine ADHD subtypes
Symptom-based ADHD diagnoses may not align with a patient's underlying neuropathy, making it harder to develop individualized treatment plans. In a new study published in Psychiatry Research, a team led by Yale School of Medicine's Bruce Wexler, MD, identified four ADHD subgroups based on biomarkers observed during digital neurotherapy.
Other Articles in this Edition
ADHD: Study finds that noninvasive brain stimulation treatment can ease symptoms
Mitochondrial Dysfunction May Be Important Biomarker for ADHD, ASD
Micro-cognition biomarkers redefine ADHD subtypes
COVID-19 led to increased anxiety for families with children with neurodevelopmental conditions
ADHD in an era of distraction: Why are more adults getting diagnosed?
ADD vs ADHD: What Are the Differences? Understanding the Types and Signs in Kids and Adults
3 Big Mistakes Parents Of Kids With ADHD Make — And How To Avoid Them
Stretching Your Dollar: How to Overcome Debt While Living With ADHD
UK children waiting 16 months on average for ADHD and autism screening – study